Enzobiotic Composition Reducing Protein-Bound Uremic Toxins
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic kidney disease (CKD) and end-stage renal disease (ESRD) are inadequate in reducing protein-bound uremic toxins, such as p-cresol and indoxyl sulfate, which contribute to cardiovascular complications and progression of renal damage, and there is a need for effective therapeutic agents to improve survival and quality of life for CKD patients, especially those with cardiovascular disease and COVID-19 infection.
Innovation Solution
An enzobiotic therapeutic combination comprising a synbiotic (probiotic and prebiotic) combined with a proteolytic enzyme, specifically Lactobacillus acidophilus, Bifidobacterium longum, Streptococcus thermophilus, fructooligosaccharide, and Bacillus subtilis protease, which reduces protein-bound uremic toxins and provides nephroprotective effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional dialysis treatment is used, then uremic toxins are removed from blood, but protein-bound uremic toxins (p-cresol and indoxyl sulfate) are difficult to remove and accumulate in the body
Solution Approach 1:
The patent introduces an enzobiotic combination as an intermediary substance that mediates the breakdown of protein-bound uremic toxins in the gastrointestinal tract. This combination includes probiotics (Lactobacillus acidophilus, Bifidobacterium longum, Streptococcus thermophilus), prebiotics (fructooligosaccharide), and proteolytic enzymes (Bacillus subtilis protease) that work together to convert protein-bound toxins into removable forms, thereby overcoming the limitation of conventional dialysis in removing these specific toxins.
Solution Approach 2:
The patent replaces the mechanical filtration system of conventional dialysis with a biochemical system operating in the gastrointestinal tract. Instead of relying solely on mechanical filtration membranes that struggle with protein-bound toxins, the invention uses biological enzymes and microorganisms to chemically transform the toxins into forms that can be more effectively removed, substituting mechanical action with biochemical action.
2Object-affected harmful factors
If undigested protein is retained in intestines, then immune response is triggered causing inflammation, but increasing morbidity and mortality in CKD patients
Solution Approach 1:
The patent applies preliminary action by introducing the enzobiotic combination that proactively digests and processes protein substrates in the gastrointestinal tract before they can be retained and trigger immune responses. The proteolytic enzymes and probiotics work in advance to break down proteins and prevent the formation of harmful undigested protein residues that would otherwise cause inflammation and increase mortality risk in CKD patients.
3Reliability
If multiple therapeutic agents are combined to treat CKD and CVD, then treatment effectiveness improves, but treatment complexity increases
Solution Approach 1:
The patent merges multiple therapeutic agents into a single integrated enzobiotic combination formulation. Instead of requiring separate administration of probiotics, prebiotics, and proteolytic enzymes, the invention combines Lactobacillus acidophilus, Bifidobacterium longum, Streptococcus thermophilus, fructooligosaccharide, and Bacillus subtilis protease into one cohesive product that can be administered together, thereby maintaining treatment effectiveness while reducing regimen complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The enzobiotic combination effectively decreases p-cresol and indoxyl sulfate levels by 20-30% and 500-1500 μg/ml, respectively, delaying dialysis, improving cardiac performance, lipid profiles, and quality of life in CKD patients, while also offering therapeutic benefits for cardiovascular and COVID-19-related renal diseases.
Implementation Method 1
at least one proteolytic enzyme, wherein said combination is capable of reducing the concentration of protein bound uremic toxins
Implementation Method 2
a synbiotic comprising at least one probiotic and at least one prebiotic
Implementation Method 3
a synbiotic comprising at least one probiotic and at least one prebiotic
Data Source
AI summary
The present invention relates to an enzobiotic therapeutic combination, process for their preparation, enzobiotic therapeutical compositions containing them and their use as a therapeutic supplement or a nutritional supplement or a food supplement in renal diseases and disorders. The said combination comprising a therapeutically effective amount of: a) a synbiotic comprising at least one prebiotic and at least one probiotic and b) at least one proteolytic enzyme. The present invention further relates to kits and methods of using them. The enzobiotic combination and the enzobiotic composition comprising the said combination is particularly useful as a therapeutic supplement or a nutritional supplement or a food supplement to prevent generation of protein bound uremic toxins generated by undigested protein, to postpone dialysis and improve quality of life in subjects suffering from chronic kidney disease and end stage renal disease.